drugset / Trial / NCT07304739
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
NaSingle-groupOpen-labelTreatment
Summary
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal and Leptomeningeal Metastases
Timeline
- Start
- 2025-12-22
- Primary completion
- 2028-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 2 mg | Other |
| Subject | Firmonertinib | Small molecule | 160 mg | Oral |
| Subject | Pemetrexed | Small molecule | 40 mg | Other |